Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes

Abstract

Contractile dysfunction is underdiagnosed in early stages of diabetic cardiomyopathy. We evaluated the potential of circulating long non-coding RNAs (lncRNAs) as biomarkers of subclinical cardiac abnormalities in type 2 diabetes. Forty-eight men with well-controlled type 2 diabetes and 12 healthy age-matched volunteers were enrolled in the study. Left ventricular (LV) parameters were measured by magnetic resonance imaging. A panel of lncRNAs was quantified in serum by RT-qPCR. No differences in expression levels of lncRNAs were observed between type 2 diabetes patients and healthy volunteers. In patients with type 2 diabetes, long intergenic non-coding RNA predicting cardiac remodeling (LIPCAR) was inversely associated with diastolic function, measured as E/A peak flow (P < 0.050 for all linear models). LIPCAR was positively associated with grade I diastolic dysfunction (P < 0.050 for all logistic models). Myocardial infarction-associated transcript (MIAT) and smooth muscle and endothelial cell-enriched migration/differentiation-associated long noncoding RNA (SENCR) were directly associated with LV mass to LV end-diastolic volume ratio, a marker of cardiac remodelling (P < 0.050 for all linear models). These findings were validated in a sample of 30 patients with well-controlled type 2 diabetes. LncRNAs are independent predictors of diastolic function and remodelling in patients with type 2 diabetes.

Expression of Long Non-Coding RNAs in Long-term Adaptation to Intense Physical Training

“…Було досліджено, що LIPCAR може служити корисним раннім діагностичним інструментом для оцінки діастолічної функції ЛШ та ремоделювання [8,9]. Враховуючи раніше досліджувану асоціацію між параметрами діастолічної функції ЛШ та рівнями експресії LIPCAR, було висунуто гіпотезу, що циркулюючі рівні цих lncRNAs можуть бути потенційними біомаркерами діастолічного порушення функції ЛШ у пацієнтів з діабетом 2 типу, які показали більш високий рівень LIPCAR порівняно з пацієнтами з нормальною діастолічною функцією [10]. MIAT бере участь у патологічному ангіогенезі, тому пропонується як пре диктор інфаркту міокарда [11].…”

Long noncoding RNAs: A new player in the prevention and treatment of diabetic cardiomyopathy?

“…Zhang's team study showed that by inhibiting lncRNA‐AK081284, interleukin‐17 ablation reduced cardiac interstitial fibrosis and improved cardiac function in diabetic mice . Gonzalo‐Calvo et al indicated that lncRNAs are independent predictors of diastolic function and remodelling in patients with type 2 diabetes . Accordingly, it is of great significance to study the regulation of lncRNA in DCM.…”

“…4 Gonzalo-Calvo et al indicated that lncRNAs are independent predictors of diastolic function and remodelling in patients with type 2 diabetes. 70 Accordingly, it is of great significance to study the regulation of lncRNA in DCM.…”

Long non‐coding RNAE330013P06 promotes progression of breast cancer with type 2 diabetes

“…Recently, long non‐coding RNAs (LncRNA) of plasma, that were thought to promote cancer development, were found to take a significant role in diabetes 2 progression . Long non‐coding RNAs are non‐coding RNAs that are longer than 200 nucleotides, and many of them were demonstrated to play a pivotal role in the development and progression of many diseases including cancer .…”

“…MT‐LIPCAR (Mitochondrially Encoded Long Non‐Coding Cardiac Associated RNA) is an RNA gene and is affiliated with the non‐coding RNA class. Diseases associated with MT‐LIPCAR include congestive heart failure and myocardial infarction . GAS5 (growth arrest specific 5) is an RNA gene and is affiliated with the non‐coding RNA class.…”